Nevada’s Top Selling CBD Line of Wellness Products Signs Agreements with Various Distribution Partners to Cover Coast to Coast Product Availability
LAS VEGAS, NV and VANCOUVER, BC / ACCESSWIRE / December 3, 2019 / Ovation Science Inc. (CSE:OVAT) (“Ovation” or the “Company”), a cannabis product development company with a patented skin delivery technology backed by twenty-plus years of research and development, announces expanded distribution of its product formulations through its US licensee Cannabiniers (Lighthouse Strategies, LLC). Ovation product formulations are sold by Cannabiniers under their brand name BASKIN Essentials in the USA. They have recently signed multiple distribution agreements across the United States, expanding its product availability coast to coast. BASKIN products are powered by Ovation’s patented skin delivery technology Invisicare® which improves CBD delivery to and through the skin. BASKIN products have been the leading topical products in Nevada dispensaries and now Ovation’s licensee is expanding their distribution through Good Titrations (AK), Pecos Valley Production (NM), Uproar Distribution (TX) and Matrix Distributors (based in NJ & KY with national distribution), as well as MarketHub (based in CO with national distribution).
“Our US licensee has successfully launched four of Ovation’s products in Nevada under the brand BASKiN with an excellent consumer response. We are excited that they have now signed multiple distribution agreements which will expand consumer access to our products in the United States,” said Terry Howlett, President of Ovation. “This adds immediate royalty revenue and shareholder value and we look forward to their continued success.”
“With creams, teas and bath bombs, BASKIN Essentials offers a product variety for the wellness consumer. Dominating sales across Nevada for the vast majority of 2019, we are thrilled to expand BASKIN’s distribution and product availability to consumers nationwide,” said Jeffry Paul, Vice President & Director of Sales for Cannabiniers. “BASKIN products are made with high-quality ingredients, backed by science, and proven to work.”
“MarketHub is leading the quality standard for the hemp products distributed to large retailers across the United States,” said Shane Nance, CEO of MarketHub. “Backed by science, BASKIN’s portfolio of effective CBD pain management products establishes the credibility and trust that retailers seek to offer their customers. The company’s commitment to science, product development and quality, vertical transparency on-pack, and educating consumers in the process leads the CBD category. We are fully aligned with BASKIN in setting and delivering on this high standard for all their CBD products.”
According to Headset data, a business intelligence company for cannabis dispensaries, BASKIN Essentials product sales consistently rank at the top by unit sales in Nevada. BASKIN’s creams have undergone rigorous scientific testing including Ovation’s Franz cell diffusion analysis, a membrane release method, skin binding and skin moisture studies. The cream’s superior binding allows it to stay bonded to the skin, resulting in continuous delivery of the active ingredient for hours and hours of effects. The portfolio of CBD personal care products licensed from Ovation have been developed using high-quality ingredients and include:
- BASKIN Skin Relief Cream – 150mg active CBD for skin conditions
- BASKIN Body Wellness Cream – 400mg active CBD for relaxation
- BASKIN Sport Recovery Cream – 300mg active CBD for pre & post workouts
Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation’s business model is to develop and market its two product lines Invibe MD and ARLO CBD Beauty as well as continuing to out-license its topical and transdermal formulations to cannabis companies globally. Ovation formulated CBD and THC products are marketed in Nevada in state-approved dispensaries by its US licensee with additional states being added. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC and Las Vegas, Nevada. Ovation trades on the CSE under the symbol OVAT. For more information visit our website: www.ovationscience.com.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR INVESTOR RELATIONS:
Phone 604.283.0903 ext. 2
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Phone: 604.283.0903 ext. 4
SOURCE: Ovation Science Inc.
View source version on accesswire.com: